Results 11 to 20 of about 34,105 (239)

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. [PDF]

, 2007
Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we
Klein, Michèl R, Friggen, Annemieke H, Geluk, Annemieke, Lin, May Young, Verduyn, Marleen JC, Voskuil, Martin I, Huygen, Kris, Franken, Kees LMC, Smith, Steven G, van Meijgaarden, Krista E, Dockrell, Hazel M, Stewart, Amanda L, Ottenhoff, Tom HM   +12 more
core   +2 more sources

Procedure for preparation, certification, and storage of a seed lot of the Mycobacterium bovis BCG-I (Russia) vaccine strain

Биопрепараты: Профилактика, диагностика, лечение, 2022
To date, the Bacillus Calmette–Guérin (BCG) vaccine has been the only medicinal product for active mass childhood immunisation against tuberculosis in the Russian Federation.
D. T. Levi, R. I. Ludannyy, Yu. I. Obukhov, A. A. Savina, A. A. Alesina, N. V. Aleksandrova   +5 more
doaj   +1 more source

Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. [PDF]

PLoS ONE, 2009
Recombinant adenovirus-vectored (Ad) tuberculosis (TB) vaccine platform has demonstrated great potential to be used either as a stand-alone or a boost vaccine in murine models.
Zhou Xing, Christine T McFarland, Jean-Michel Sallenave, Angelo Izzo, Jun Wang, David N McMurray   +5 more
doaj   +1 more source

The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. [PDF]

, 2012
BACKGROUND: Globally, BCG vaccination varies in efficacy and has some non-specific protective effects. Previous studies comparing BCG strains have been small-scale, with few or no immunological outcomes and have compared TB-specific responses only.
Webb, Emily L, Nampijja, Margaret, Anderson, Elizabeth J., Anderson, Elizabeth J, Mawa, Patrice A, Lyadda, Nancy, Elliott, Alison M, Webb, Emily L., Elliott, Alison M., Mawa, Patrice A., Kizza, Moses   +10 more
core   +1 more source

Outbreak of Bacille Calmette-Guérin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine

Annals of Saudi Medicine, 2012
BACKGROUND AND OBJECTIVES: Bacille Calmette-Guérin (BCG) vaccination is part of the expanded program of vaccination in Saudi Arabia. Lymphadenitis is the most common complication of the BCG vaccine.
Abdulkarim Abdullah Alrabiaah, Sarah Suliman Alsubaie, Elham Issa Bukhari, Ashry Gad, Fahad Abdullah Alzamel   +4 more
doaj   +1 more source

Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. [PDF]

PLoS Neglected Tropical Diseases, 2016
Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells ...
Bryan E Hart, Sunhee Lee
doaj   +1 more source

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]

, 2012
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Minassian, Angela M, Porter, David W, Pathan, Ansar A, Rowland, Rosalind, Sander, C, Satti, Iman, Angela M Minassian, Nicola Williams, Lawrie, AM, Sander, Clare, Alison M Lawrie, Rowland, R, Poulton, ID, Rosalind Rowland, Brittain, N, Williams, Nicola, Pathan, AA, David W Porter, Minassian, AM, Helen McShane, Iman Satti, Ansar A Pathan, Ian D Poulton, Lawrie, Alison M, Nathaniel Brittain, Williams, N, Brittain, Nathaniel, Poulton, Ian D, Clare Sander, Porter, DW, Satti, I, McShane, H, McShane, Helen   +32 more
core   +1 more source

Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination. [PDF]

, 2012
: Heparin-binding haemagglutinin (HBHA)-specific immune responses have been linked to protection against tuberculosis (TB). We investigated the hypothesis that BCG vaccination of human infants primes an HBHA-specific response, using multiplex to measure ...
Smith, SG, Locht, Camille, Lecher, S, Locht, C, Dockrell, HM, Smith, Steven G, Lecher, Sophie, Blitz, Rose, Dockrell, Hazel M, Blitz, R   +9 more
core   +2 more sources

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

mBio, 2016
Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002)
Helen A. Fletcher
doaj   +1 more source

Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia

Vaccines, 2021
Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only live attenuated vaccine available against tuberculosis. The first BCG vaccination was done exactly 100 years ago, in 1921.
Stefan Panaiotov, Yordan Hodzhev, Vladimir Tolchkov, Borislava Tsafarova, Alexander Mihailov, Tzvetelina Stefanova   +5 more
doaj   +1 more source